Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Abstract Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemothe...

Full description

Bibliographic Details
Main Authors: J. M. Vicencio, R. Evans, R. Green, Z. An, J. Deng, C. Treacy, R. Mustapha, J. Monypenny, C. Costoya, K. Lawler, K. Ng, K. De-Souza, O. Coban, V. Gomez, J. Clancy, S. H. Chen, A. Chalk, F. Wong, P. Gordon, C. Savage, C. Gomes, T. Pan, G. Alfano, L. Dolcetti, J. N. E. Chan, F. Flores-Borja, P. R. Barber, G. Weitsman, D. Sosnowska, E. Capone, S. Iacobelli, D. Hochhauser, J. A. Hartley, M. Parsons, J. N. Arnold, S. Ameer-Beg, S. A. Quezada, Y. Yarden, G. Sala, T. Ng
Format: Article
Language:English
Published: Nature Publishing Group 2022-03-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-04701-3

Internet

https://doi.org/10.1038/s41419-022-04701-3

Similar Items